Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Moleculin Biotech, Inc.

Get SEC filing alerts via email and in your feed for Moleculin Biotech, Inc.

MBRX

Moleculin Biotech, Inc.

About Moleculin Biotech, Inc.

Moleculin Biotech is a late-stage pharmaceutical company focused on developing innovative cancer therapies. Its lead drug, Annamycin, is a non-cardiotoxic anthracycline targeting relapsed/refractory AML and lung metastases, with potential applications in hard-to-treat cancers. The company advances its portfolio through clinical trials, leveraging proprietary lipid technology and collaborations with academic institutions to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Moleculin Biotech, Inc.

1
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $12.8 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $33.6 Million Net Loss for 2025, Advances Annamycin in Phase 3 Trial

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $25.4 Million Net Loss in Q3 2025, Faces Financing Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $7.6 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $6.4 Million Net Loss in Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Moleculin Biotech, Inc. Moleculin Biotech Reports $21.8 Million Net Loss for 2024, Focuses on Annamycin Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Moleculin Biotech, Inc. Moleculin Biotech Reports Decline in Cash and Assets, Net Loss Increases in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments